Raystation
Raysearch Laboratories Ab (Publ)
FDA Clearance Information
RayStation was cleared via the FDA 510(k) pathway on April 8, 2016. It is manufactured by Raysearch Laboratories Ab (Publ) and is classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- For use as a radiation therapy treatment planning system.
- For calculating and optimizing radiation dose distributions for radiation therapy treatment plans.
- For use with supported radiation therapy treatment modalities and clinical planning workflows described in the device labeling.
Clinical Applications
- Planning proton beam radiation therapy.
- Planning external-beam radiation therapy treatments.
- Calculating radiation dose distributions for treatment plans.
- Optimizing treatment plans to support delivery of the prescribed radiation dose.
- Comparing treatment plans or imaging-based planning scenarios when supported by the configured system.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- RayStation is software rather than an implanted or wearable device, so it does not have a physical size, catheter diameter, or vessel-compatibility specification.
- Use requires compatible hardware, imaging data, radiation therapy equipment, and appropriately trained radiation oncology personnel.
- MRI images may be used for planning only when the imaging workflow, registration, and tissue-density conversion are validated by the treating institution; MRI compatibility of the software does not make an MRI scanner or accessories safe.
- Treatment plans require clinical review, quality assurance, and verification before radiation is delivered.
- The system is not a substitute for physician prescription, treatment planning judgment, or facility-specific safety protocols.
Frequently Asked Questions
What are the clinical indications for RayStation?
RayStation is indicated for use in radiation therapy planning, particularly for proton therapy and other advanced radiotherapy techniques.
What outcomes have been reported in clinical studies?
Studies have reported improved treatment plan quality and optimization capabilities, particularly in proton therapy.
What complications have been reported?
Safety data indicate challenges in dose calculation accuracy and parameter selection, but no significant adverse events have been reported.